Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
IntelliCell Biosciences Announces That It Is Collaborating With the Global Alliance for Innovation in Neuroscience, Inc. (GAIN) for Autism, Dementia and Brain Trauma
Marketwired IntelliCell BioSciences, Inc. Mar 19, 2014 9:30 AM
NEW YORK, NY--(Marketwired - Mar 19, 2014) - IntelliCell Biosciences, Inc. ("IntelliCell" or the "Company") (OTCQB: SVFC), a regenerative medicine company utilizing adult autologous vascular cells (SVCs) derived from the blood vessels found in adipose tissue, announced today that it will be entering into a collaboration with the Global Alliance for Innovation in Neuroscience, Inc. (GAIN) to use its unique approach to the harvest and use of autologous adipose derived mesenchymal stem cells for clinical neuroscience applications including autism, dementia and brain trauma.
GAIN, a translational neuroscience research organization, designs and develops innovative neuroimaging technologies and computer analyses to assess and treat a variety of neuropsychiatric disorders. GAIN has extensive experience in the imaging and treatment of autism, dementia, brain trauma and other neurological disorders.
IntelliCell BioSciences and GAIN are developing joint protocols with initial efforts focusing on the assessment and treatment of children and adults with Autism, Alzheimer's Dementia, and returning warfighters with blast induced traumatic brain injury. Dr. Sandlin Lowe of the Amen Clinic will lead the studies and treatment of Autism and Alzheimer's disease using Intellicell's patented ultrasonic technology.
IntelliCell's Chief Executive Officer, Dr. Steven Victor, remarked, "This is a tremendously moving moment for IntelliCell to work with Dr. Lowe and GAIN on viable treatments for Autism, a disease that continues to grow in our society with unmet clinical needs. We believe that the Intellicell's Stromal Vascular Fraction Cells will offer adults and children with autism a significant improvement in their quality of life. IntelliCell's cellular therapy has also been used to successfully enhance the life of a veteran who had sustained a traumatic brain injury while on duty in Iraq. We believe that the stromal vascular fraction cells have the potential to revolutionize the treatment of Alzheimer's disease as well. We at IntelliCell are excited to have this opportunity to work with the distinguished neuroscientist, Dr Lowe."
According to Sandlin Lowe, MD, Co-Founder and Director of GAIN and Consulting Clinician to the Amen Clinics New York, "Dr. Victor's approach to stem cell treatments is revolutionary. The IntelliCell BioSciences / GAIN collaboration will expand the use of autologous mesenchymal stem cells derived by sonification of the stromal vascular fraction of adipose tissue for many neuropsychiatric conditions including autism, dementia and brain injury.
"We at GAIN look forward to an exciting and fruitful collaboration with IntelliCell BioSciences as together we pioneer new methods in translational neuroscience for the imaging and treatment of autism, Alzheimer's dementia, and brain blast injuries," says Dr. Lowe.
About IntelliCell Biosciences
IntelliCell is a pioneering regenerative medicine company focused on the expanding regenerative medical markets using adult autologous stromal vascular fraction cells (SVFCs) derived from the blood vessels in the adult adipose tissue. IntelliCell BioSciences has developed its own patented technology and protocol to separate adult autologous vascular cells from adipose tissue without the use of enzymes. IntelliCell will also be seeking to develop technology-licensing agreements with technology developers, universities, and international business entities.
About Dr. Sandlin Lowe
Dr. Lowe specializes in the treatment for cognitive decline including dementia, traumatic brain injury, Autism and other neurodevelopmental disorders.
Dr. Sandlin Lowe left the family farm in Coosa County, Alabama to study Anthropology and later obtain his MD degree from Tulane University in New Orleans by 1987. He was on the Faculty of the New York University School of Medicine where he holds appointments in both the Department of Psychiatry and the Department of Physiology and Neuroscience. He is Consulting Neuropsychiatrist to the NYU School of Medicine Brain Research Laboratories and Collaborating Psychiatrist at the NYU Langone Center for Neuromagnetism. After 18 years of service and research at Bellevue Hospital Center (for which he was honored with a Congressional Award), Dr. Lowe has become the Chief of Psychiatry Assessment Services at the NYU - Woodhull Medical and Mental Health Center, an affiliate institution of the NYU Langone Medical Center and the New York University School of Medicine.
Dr. Lowe is an expert in Translational Clinical Neuroscience and Therapeutics. He is co-founder and Director of the Global Alliance for Innovation in Neuroscience, Inc. (GAIN) along with the GAIN Labs and GAIN Health. Dr. Lowe has created new paradigms for the conceptualization, evaluation and treatment of patients with neuropsychiatric conditions. The theoretical basis for this work is founded upon his research with Dr. Rodolfo Llinas and Dr. E. Roy John, two of the Fathers of modern day neuroscience.
In the past few years, for personal reasons, Dr. Lowe's efforts have been directed towards autism spectrum disorders. He has special interests in abnormal neural dynamic states, particularly thalamocortical dysrhythmias, and how they manifest as major pathophysiological mechanisms in neurodevelopmental disorders, traumatic brain injuries, cognitive impairment/decline and dementia. He now is specifically engaged in the search for the etiologies of these dysrhythmias and treatments for them. Currently Dr. Lowe and his colleagues are at work combining small molecules, biologicals, and cellular and regenerative medicine therapeutics with transcranial magnetic stimulation (rTMS) and other applied field energy methods in the design of new treatment protocols for autism, acquired brain injuries, and conditions of cognitive impairment/decline and dementia.
IntelliCell BioSciences' Stromal Vascular Cell Technology Used For Restorative Cardiac Function With Dr. Zain Khalpey
PR Newswire IntelliCell BioSciences, Inc. Apr 29, 2014 1:32 PM
NEW YORK, April 29, 2014 /PRNewswire/ -- IntelliCell BioSciences, Inc. ("IntelliCell" or the "Company") (SVFC), a regenerative medicine company utilizing adult autologous Stromal Vascular Cells (SVCs) derived from the blood vessels found in adipose tissue, announced today that it supplied its Stromal Vascular Fraction Cells, manufactured using its patented ultrasonic technology, for the restoration of cardiac function at the University of Arizona College of Medicine, Tucson in collaboration with Dr. Zain Khalpey, Division of Cardiothoracic Surgery. The autologous cells were gathered on site with Institutional Review Board approval in accordance with all applicable regulatory requirements. The case was reported in Clinical Communication to the Editor in The American Journal of Medicine Vol.127, No 5, May 2014.
http://www.amjmed.com/article/S0002-9343(14)00079-5/fulltext
According to Dr. Zain Khalpey's conclusions in the clinical communications to The American Journal of Medicine, "We postulate that the intramyocardial administration of multi-potent adipose-derived stromal vascular fraction cells and their diverse composition guided engraftment in the damaged area, facilitated the cardiomyocyte regenerative properties, and helped improve cardiac function. Because subcutaneous adipose tissue is readily available in most patients, adipose-derived stromal vascular fraction cells present a feasible clinical intervention for cardiac dysfunction. The population complexity, which includes stromal vascular fraction and growth factors, likely promotes repair by recruiting cardiomyocytes. The autologous nature and multi-potency of these cells may contribute to them being ideal for cardiac function restoration."
IntelliCell's Chief Executive Officer, Dr. Steven Victor, remarked, "This is a momentous point for Intellicell Biosciences illustrating that its Stromal Vascular Fraction Cells (SVFC) and its technology have clinical promise in the restoration of cardiac function. I believe Dr. Khalpey's theory of injecting the SVFCs intracardiac externally and intravenously under a compassionate IRB, will pave the way for our FDA IND study that will focus on Congestive Heart Failure. This IND study will be important for proving the company's patented technology of Ultrasonic Cavitation as a method of separating stromal vascular fraction cells from lipoaspirate. We believe that IntelliCell's Stromal Vascular Fraction Cells injected into the cardiac muscle externally and given intravenously will make a significant clinical difference. We at IntelliCell would like to thank Ms. Stephanie Squicciarini for flying out to Tucson, Arizona with our lab and manufacturing the SVFCs in the operating room for Dr. Khalpey."
About IntelliCell Biosciences
IntelliCell is a pioneering regenerative medicine company focused on the expanding regenerative medical markets using adult autologous stromal vascular fraction cells (SVFCs) derived from the blood vessels in the adult adipose tissue. IntelliCell BioSciences has developed its own patented technology and protocol to separate adult autologous vascular cells from adipose tissue without the use of enzymes. IntelliCell will also be seeking to develop technology-licensing agreements with technology developers, universities, and international business entities.
About Dr. Zain Khalpey according to the University of Arizona website
Born in Africa, Dr. Khalpey completed his medical education in the UK and studied and worked extensively throughout Europe and the United States before deciding to pursue his organ transplantation research at the University of Arizona, the birthplace of the Total Artificial Heart.
In addition to his clinical work at The University of Arizona Medical Center, where he recently was appointed director of the internationally renowned heart transplant program and mechanical circulatory support, Khalpey is involved in numerous research activities, focused mainly in three key areas: bridge to regeneration, organ reconditioning and organogenesis, or the creation of new organs.
The first area, bridge to regeneration, focuses on reducing the number of people who require heart transplants by improving stem cell treatments for failing hearts.
http://surgery.arizona.edu/faculty-profile/zain-khalpey-md-phd-mrcs
About Arizona College of Medicine according to website
For more than a decade, The University of Arizona Medical Center has been ranked among the nation's best hospitals by U.S. News & World Report.
The University of Arizona Health Network is Arizona's first academic medical network. It includes The University of Arizona Medical Center - University Campus, The University of Arizona Medical Center - Diamond Children's, The University of Arizona Medical Center - South Campus, some 40 clinics, a health plan division and the practice plan for physicians from the University of Arizona College of Medicine. It's been nationally recognized for providing exceptional patient care, teaching new health care professionals and conducting groundbreaking research through the physician-scientists of the University of Arizona College of Medicine.
IntelliCell BioSciences Files Pre-IND With FDA for Osteoarthritis Lead by Dr. James Andrews
Marketwired IntelliCell BioSciences, Inc. Aug 1, 2014 1:52 PM
NEW YORK, NY--(Marketwired - Aug 1, 2014) - IntelliCell BioSciences, Inc. ("IntelliCell" or the "Company") (OTCQB: SVFC), a regenerative medicine company utilizing adult autologous stomovascular cells (SVCs) derived from the blood vessels found in adipose tissue, announced today that it has filed its pre-IND with the FDA for a clinical trial in osteoarthritis of the knee under an Investigational New Drug Application (IND). Dr. James Andrews, the legendary orthopedic surgeon will be the principal investigator for the study. inVentiv Health Clinical will serve as the Clinical Research Organization (CRO) for the conduction of this clinical trial in osteoarthritis of the knee in accordance of an Investigational New Drug.
IntelliCell BioSciences and Dr. James Andrews are developing the investigational clinical study protocols in collaboration with inVentiv Clinical, functioning as the CRO. The clinical trial will be conducted at the Pensacola Center of the Andrews' Research and Educational Institute in conjunction with Dr. Adam Anz and Dr. Josh Hackel, prominent physicians at the Institute. To date, IntelliCell's technology for isolating stromal vascular fraction cells from the vasculature of adipose tissue has been used to successfully treat over 60 knees with results lasting as long as 5 years.
IntelliCell's Chief Executive Officer, Dr. Steven Victor, remarked, "This is a pivotal point for IntelliCell BioSciences as it will be what we believe to represent the first of many clinical trials that the company will undertake and establish the company as a leader in the cellular therapy segment of the biotech industry. This IND study is important for verifying the company's patented technology of utilizing Ultrasonic Cavitation as a method of separating stromal vascular fraction cells from lipoaspirate. We believe that IntelliCell's Stromal Vascular Fraction Cells will offer people with OA a new and improved approach to gaining significant improvements in their qualities of life. We at IntelliCell are excited to have this opportunity to work with the distinguished Sports Medicine Orthopedic Surgeon, Dr. James Andrews, who will be the principal investigator of this clinical trial."
According to Raymond Hill, President of inVentiv Clinical, "inVentiv Clinical has extensive therapeutic experience in general pain and osteoarthritis programs and a focus on partnering with innovative bioscience companies. We are looking forward to our working with Dr. Andrews and contributing to advances in the treatment of osteoarthritis in knees."
Dr. James Andrews said, "We are excited that we will have the opportunity to work with inVentiv Clinical Health as the CRO for our IND study of osteoarthritis of the knee using IntelliCell's technology. It will be research like this at the Andrews' Research and Educational Institute in collaboration with IntelliCell BioSciences and inVentiv that will further our research in the use of the biologics for the treatment of the osteoarthritic knee. We believe, based on antidotal evidence of others, that this cellular therapy has the potential to be a game changer."
Skinspirations Study Supports Medical Findings: Stem Cell Treatment Triggers Tissue Regeneration
Medical discoveries continue to reveal the many uses for which stem cell treatment can be used, ranging from kidney disease to brain damage. A recent case study conducted by Skinspirations demonstrated the healing results that stem cell treatment induces in patients with osteoarthritis.
http://www.prweb.com/releases/2014/07/prweb11995836.htm
New hope for paralysed patients: Scientists grow links between spinal cord and the brain for the first time
U.S. scientists have regrown spinal cord neurons from a patient’s own cells
They implanted the cells in injured rats aiming to reverse paralysis
Found neurons caused animals' nervous system to rewire the spinal cord
Connections extended into rats' limbs but they couldn't walk again
Experiment offers hope to paralysed people as scientists get closer to cure
But expert warns it could be months or years before human trials
Read more: http://www.dailymail.co.uk/health/article-2719783/New-hope-paralysed-patients-Scientists-grow-links-spinal-cord-brain-time.html#ixzz3ADe2ykiP
Follow us: @MailOnline on Twitter | DailyMail on Facebook
http://www.dailymail.co.uk/health/article-2719783/New-hope-paralysed-patients-Scientists-grow-links-spinal-cord-brain-time.html?ITO=1490&ns_mchannel=rss&ns_campaign=1490
Clinical trial evaluates safety of stem cell transplantation in spine
Date:
August 11, 2014
Source:
University of California, San Diego Health Sciences
Summary:
A clinical trial to investigate the safety of neural stem cell transplantation in patients with chronic spinal cord injuries has been launched in the United States. Related goals of the clinical trial include evaluating the stem cell graft's survival and the effectiveness of immunosuppression drugs to prevent rejection. The researchers will also look for possible therapeutic benefits such as changes in motor and sensory function, bowel and bladder function, and pain levels.
Researchers at the University of California, San Diego School of Medicine have launched a clinical trial to investigate the safety of neural stem cell transplantation in patients with chronic spinal cord injuries. This Phase I clinical trial is recruiting eight patients for the 5-year study.
"The goal of this study is to evaluate the safety of transplanting neural stem cells into the spine for what one day could be a treatment for spinal cord injuries," said Joseph Ciacci, MD, principal investigator and neurosurgeon at UC San Diego Health System. "The study's immediate goal, however, is to determine whether injecting these neural stem cells into the spine of patients with spinal cord injury is safe."
Related goals of the clinical trial include evaluating the stem cell graft's survival and the effectiveness of immunosuppression drugs to prevent rejection. The researchers will also look for possible therapeutic benefits such as changes in motor and sensory function, bowel and bladder function, and pain levels.
Patients who are accepted for the study will have spinal cord injury to the T7-T12 level of the spine's vertebrae and will have incurred their injury between one and two years ago.
All participants will receive the stem cell injection. The scientists will use a line of human stem cells approved by the U.S. FDA for human trials in patients with chronic traumatic spinal injuries. These cells were previously tested for safety in patients with amyotrophic lateral sclerosis (ALS).
Since stem cell transplantation for spinal cord injury is just beginning clinical tests, unforeseen risks, complications or unpredictable outcomes are possible. Careful clinical testing is essential to ensure that this type of therapy is developed responsibly with appropriate management of the risks that all medical therapies may present.
Pre-clinical studies of these cells by Ciacci and Martin Marsala, MD, at the UC San Diego School of Medicine, showed that these grafted neural stem cells improved motor function in spinal cord injured rats with minimal side effects indicating that human clinical trials are now warranted.
http://www.sciencedaily.com/releases/2014/08/140811151420.htm
Cedars-Sinai Heart Institute Opens First-of-its-Kind Research Stem Cell Clinic for Cardiac Patients
Physicians to Devise Comprehensive Treatment Strategies, Evaluate Patients for Inclusion in Ongoing Stem Cell Clinical Trials
Released: 12-Aug-2014 8:00 AM EDT
Source Newsroom: Cedars-Sinai Medical Center
more news from this source
Contact Information
Available for logged-in reporters only
Newswise — LOS ANGELES (Aug. 12, 2014) – Regenerative medicine experts at the Cedars-Sinai Heart Institute have opened a new clinic to evaluate heart and vascular disease patients for participation in stem cell medical studies.
Led by Eduardo Marbán, MD, PhD, director of the Cedars-Sinai Heart Institute, and Timothy Henry, MD, director of the Heart Institute’s Cardiology Division, the doctors and researchers at the Cedars-Sinai Heart Institute Regenerative Medicine Clinic use a scientific approach to assess the possible benefits of stem cells to repair damaged or diseased cardiovascular tissues. The clinic is believed to be the first at a major U.S. academic medical center dedicated to matching patients with appropriate stem cell clinical trials, whether those research interventions are available at the medical center or at other institutions.
The Heart Institute Regenerative Medicine Clinic offers consultative services for patients with heart and vascular disease who may qualify for investigative stem cell therapy. The goal is to provide research options to patients who remain symptomatic on their current management regimen, or for patients with stable heart disease who are concerned about disease progression.
“Over the past decade, medical experts have predicted that in the future, stem cell therapies would transform heart disease treatment and save lives,” said Shlomo Melmed, MD, dean of the Cedars-Sinai faculty and the Helene A. and Philip E. Hixon Distinguished Chair in Investigative Medicine. “At Cedars-Sinai, we have a track record of successfully directing cardiac stem cell studies as well as transferring innovations from the laboratory to the patient bedside.”
In 2009, Marbán and his team completed the world’s first procedure in which a patient’s own heart tissue was used to grow specialized heart stem cells. The specialized cells were then injected back into the patient’s heart in an effort to repair and re-grow healthy muscle in a heart that had been injured by a heart attack. Results, published in The Lancet in 2012, showed that one year after receiving the stem cell treatment, heart attack patients demonstrated a significant reduction in the size of the scar left on the heart muscle after a heart attack.
Henry has served as principal investigator of multiple large, multicenter trials in acute coronary syndromes, myocardial infarction and angiogenesis, including several ongoing cardiovascular stem cell trials. He also is principal investigator for one of seven NIH Clinical Cardiovascular Stem Cell Centers.
“Our goal is to help make stem cells a regular treatment option for heart disease,” Henry said. “Right now, many patients with advanced heart disease have limited treatment options. Stem cells offer not only hope but a real chance of a game-changing treatment.”
As part of each patient’s assessment in the Heart Regenerative Medicine Clinic, physicians will evaluate patients interested in participating in stem cell clinical trials at Cedars-Sinai and, for patients willing to travel at other medical institutions across the nation. For patients willing to travel to participate in research, Cedars-Sinai physicians will work closely with investigators at other centers to expedite referrals and seamlessly transfer all relevant medical records.
“Patients who have battled heart failure, heart attacks and severe hypertension for years might not be aware of new options that could improve their health and quality of life,” Marbán said. “Not every patient will find a suitable stem cell clinical trial, but we are focused on finding each patient the most advanced treatment for their disease.”
To make an appointment for a preliminary evaluation, patients should call toll free 855-STEM-WORK (855-783-6967) or 310-423-1231.
About the Cedars-Sinai Heart Institute
The Cedars-Sinai Heart Institute is internationally recognized for outstanding heart care built on decades of innovation and leading-edge research. From cardiac imaging and advanced diagnostics to surgical repair of complex heart problems to the training of the heart specialists of tomorrow and research that is deepening medical knowledge and practice, the Cedars-Sinai Heart Institute is known around the world for excellence and innovations.
http://www.newswise.com/articles/view/621735/?sc=rsmn
SVFC OVERSOLD
svfc oversold
Somebody is securing more .0014's today!!
Go SVFC
Maybe today???
Go SVFC
If "Vic" is giving his wife shares as you claim, that would mean that "vic" and his wife see value in the shares. Yes?
Go SVFC
If someone wanted to sell 22million shares why would they sell at .0013 and not sell at.0014 when they could have clearly done so all day long. Also when you look at L2 it is clear that .0014's were being bought hard all day and when the ask got thin there would be a very small sale @ .0013 then reload the ask and buy up all the .0014's and repeat. MM's are playing games and picking up cheep shares only when they have their fill will they let it run. And trust me they will let it run, that is how they make their money ( buy low sell high) SVFC is majorly oversold and will make a run soon. Hang in there, don't get discouraged the MM's are very good at what they do ( steal shares) don't let them get yours
You funny. Ha ha
T-trade then. Sorry about the wrong wording. I think everybody knows what I ment
Go SVFC
22million after hours trade only looks like a sell in reality it was a buy on a down tic common mm games,
Someone has been loading huge Friday and today!
Don't be fooled by the mm games Big money is buying for a big run!!!
Go SVFC
Someone is loading .0014's big time!!
Go SVFC
Hint, Hint
SVFC
Sierra World Equity
Saturday, May 10, 2014
Low Hanging Fruit_Roche Returns To Scoop Up IntelliCell BioSciences (SVFC) In Cash And Stock Transaction Predicts Sierra World Equity Review
Latest Projections: Low Hanging Fruit_Roche Returns To Scoop Up IntelliCell BioSciences (SVFC) In Cash And Stock Transaction Predicts Sierra World Equity Review. Big things about to happen here, remember when the official word comes, Sierra called this first!
Monday May 12th 2014
Special ALERT From The Office Of The Publisher Of Sierra World Equity Review
http://sierraworldequityreview.blogspot.com/2014/05/low-hanging-fruitroche-returns-to-scoop.html?m=1
Dido!!!
Go SVFC
Do yourself a favor and cancel you're sell orders or at a minimum rase them a few tics. This week is looking very good for the pps . A major bounce and possibly a full reversal should take place this week!
Don't say I didn't warn ya
Go SVFC
SVFC Double bottom bounce play and long term reversal!!!
SVFC + BOUNCE = $$$$$
This is a "GAME CHANGER" !!!!
IntelliCell BioSciences Files Pre-IND With FDA for Osteoarthritis Lead by Dr. James Andrews
Marketwired IntelliCell BioSciences, Inc. Aug 1, 2014 1:52 PM
NEW YORK, NY--(Marketwired - Aug 1, 2014) - IntelliCell BioSciences, Inc. ("IntelliCell" or the "Company") (OTCQB: SVFC), a regenerative medicine company utilizing adult autologous stomovascular cells (SVCs) derived from the blood vessels found in adipose tissue, announced today that it has filed its pre-IND with the FDA for a clinical trial in osteoarthritis of the knee under an Investigational New Drug Application (IND). Dr. James Andrews, the legendary orthopedic surgeon will be the principal investigator for the study. inVentiv Health Clinical will serve as the Clinical Research Organization (CRO) for the conduction of this clinical trial in osteoarthritis of the knee in accordance of an Investigational New Drug.
IntelliCell BioSciences and Dr. James Andrews are developing the investigational clinical study protocols in collaboration with inVentiv Clinical, functioning as the CRO. The clinical trial will be conducted at the Pensacola Center of the Andrews' Research and Educational Institute in conjunction with Dr. Adam Anz and Dr. Josh Hackel, prominent physicians at the Institute. To date, IntelliCell's technology for isolating stromal vascular fraction cells from the vasculature of adipose tissue has been used to successfully treat over 60 knees with results lasting as long as 5 years.
IntelliCell's Chief Executive Officer, Dr. Steven Victor, remarked, "This is a pivotal point for IntelliCell BioSciences as it will be what we believe to represent the first of many clinical trials that the company will undertake and establish the company as a leader in the cellular therapy segment of the biotech industry. This IND study is important for verifying the company's patented technology of utilizing Ultrasonic Cavitation as a method of separating stromal vascular fraction cells from lipoaspirate. We believe that IntelliCell's Stromal Vascular Fraction Cells will offer people with OA a new and improved approach to gaining significant improvements in their qualities of life. We at IntelliCell are excited to have this opportunity to work with the distinguished Sports Medicine Orthopedic Surgeon, Dr. James Andrews, who will be the principal investigator of this clinical trial."
According to Raymond Hill, President of inVentiv Clinical, "inVentiv Clinical has extensive therapeutic experience in general pain and osteoarthritis programs and a focus on partnering with innovative bioscience companies. We are looking forward to our working with Dr. Andrews and contributing to advances in the treatment of osteoarthritis in knees."
Dr. James Andrews said, "We are excited that we will have the opportunity to work with inVentiv Clinical Health as the CRO for our IND study of osteoarthritis of the knee using IntelliCell's technology. It will be research like this at the Andrews' Research and Educational Institute in collaboration with IntelliCell BioSciences and inVentiv that will further our research in the use of the biologics for the treatment of the osteoarthritic knee. We believe, based on antidotal evidence of others, that this cellular therapy has the potential to be a game changer."
SVFC "GAME CHANGER"
Monday should bring a very nice bounce in the pps and the rest of the week may shape up to be one of the best weeks for SVFC in a long time!
Is it just going to be a bounce play? Or will this week be the start of a full reversal?
One thing for sure; SVFC is oversold and will correct from these levels!
is it tomorrow yet?!!!
GO SVFC
SVFC $$$$ Updated DD for newbies:)
NEWS!!!! SVFC announces a FINAL POSITIVE RULING ruling against Ironridge Global (aka, SVFC auctioneer/toxic financier) after an arduous and excruciating 10 month legal battle! Will punitive damages be awarded to SVFC???? Shareholders think this would be appropriate....but we will have to wait and see:)))
http://ih.advfn.com/p.phppid=nmona&article=62108504
NOW....The potential is enormous! LQQK at this!!!
THREE International Patents pending...one in Final Stage of Grant with two to follow, a positive International written preliminary opinion by the Patent Cooperation Treaty for all three core requirements; Novelty, Inventive Step and Industrial Applicability!...and the US Patented Stem Cell Technology verified by Millipore:)
Publication in The American Journal of Medicine, May 2014, "First in Man: Adipose-derived Stromal Vascular Fraction Cells May Promote Restorative Cardiac Function" showing positive results of cardiac function using SVFC's US Patented Stem Cell technology, brings awareness to the Regenerative Medical community and will initiate another FDA IND for Congestive Heart failure.
http://www.amjmed.com/article/S0002-9343(14)00079-5/fulltext
http://ih.advfn.com/p.php?pid=nmona&article=62010474
http://surgery.arizona.edu/faculty-profile/zain-khalpey-md-phd-mrcs
http://opa.ahsc.arizona.edu/newsroom/news/2013/heart-surgeon-zain-khalpey-appointed-lead-heart-transplant-program-mechanical-cir
Recently appointed Clinical Research Organization (CRO), InVentive Clinical,is ANOTHER STRATEGIC DEVELOPMENT to facilitate clinical trials and IND application for SVFC's patented technology in the research and treatment of knee osteoarthritis at the Andrews' Research and Education Foundation.
http://ih.advfn.com/p.php?pid=nmona&article=61836784
Licensing agreement with the internationally known Andrews's Research and Educational Foundation, as well as the IND to be filed for Knee Osteoarthritis, is a strategic move to position SVFC Patented Stem Cell Technology as the golden standard in the area of orthopedic/sports and regenerative medicine:)
http://ih.advfn.com/p.php?pid=nmona&article=61427219
http://www.theandrewsinstitute.com/InjuryPrevention/STOPSportsInjuries.aspx
Filing an IND for research and treatment of knee osteoarthritis in a consulting agreement with Dr. Anz and Dr. Hackel of the Andrews's Research and Education Foundation, will enable SVFC's patented stem cell tech to treat orthopedic and sports medicine injuries in compliance with the FDA.
http://ih.advfn.com/p.php?pid=nmona&article=61476597
Collaboration with the Global Alliance for Innovation in Neuroscience to utilize SVFC patented Stem Cell technology for the treatment of autism, dementia, brain trauma and neurological disorders will bring international recognition to Intellicell.
http://ih.advfn.com/p.php?pid=nmona&article=61509178
Research collaboration with Dr. Trujillo to develop clinical studies in the treatment of ALS using Intellicell's SVF cells and conducted under an Investigational New Drug Application will provide new found hope for individuals afflicted with the debilitating effects of ALS.
http://ih.advfn.com/p.php?pid=nmona&article=61566989
http://ih.advfn.com/p.php?pid=nmona&article=61612564
http://ih.advfn.com/p.php?pid=nmona&article=61697331
http://patentscope.wipo.int/search/en/detail.jsf?docId=WO2014036094&recNum=1&office=&queryString=FP%3A%28intellicell%29&prevFilter=&sortOption=Pub+Date+Desc&maxRec=7
http://patentscope.wipo.int/search/en/detail.jsf?docId=WO2012091911&recNum=4&office=&queryString=FP%3A%28intellicell+Biosciences%29&prevFilter=&sortOption=Pub+Date+Desc&maxRec=6
https://register.epo.org/application?number=EP11854049&lng=en&tab=event
http://pericles.ipaustralia.gov.au/ols/auspat/applicationDetails.do?applicationNo=2011352928
http://ih.advfn.com/p.php?pid=nmona&article=59699971
As the new Chairman of the IntelliCell Orthopedic Cellular Therapy Advisory Board, Dr. James Andrews stated, "We at the Andrews's Research and Educational Foundation have recently joined forces with Intelicell BioSciences to participate in their autologous stem cell research. We are excited at the opportunity of developing a first class biological laboratory at our facility in conjunction with Intelicell BioSciences that will allow us to continue our effort towards excellence in clinical stem cell therapy research."
http://ih.advfn.com/p.php?pid=nmona&article=61427219
Dr. James Andrews said, "We are excited that we will have the opportunity to work with inVentiv Clinical Health as the CRO for our IND study of osteoarthritis of the knee using IntelliCell's technology. It will be research like this at the Andrews' Research and Educational Institute in collaboration with IntelliCell BioSciences and inVentiv that will further our research in the use of the biologics for the treatment of the osteoarthritic knee. We believe, based on antidotal evidence of others, that this cellular therapy has the potential to be a game changer."
http://ih.advfn.com/p.php?pid=nmona&article=61836784
According to Sandlin Lowe, MD, Co-Founder and Director of GAIN and Consulting Clinician to the Amen Clinics New York, "Dr. Victor's approach to stem cell treatments is revolutionary. The IntelliCell BioSciences / GAIN collaboration will expand the use of autologous mesenchymal stem cells derived by sonification of the stromal vascular fraction of adipose tissue for many neuropsychiatric conditions including autism, dementia and brain injury."
"We at GAIN look forward to an exciting and fruitful collaboration with IntelliCell BioSciences as together we pioneer new methods in translational neuroscience for the imaging and treatment of autism, Alzheimer's dementia, and brain blast injuries," says Dr. Lowe.
http://ih.advfn.com/p.php?pid=nmona&article=61509178
As said by Dr. Adam Anz, "Dr. Victor, through Intellicell Biosciences, has been a pioneer in the clinical application of stem cell therapy in the United States. His interactions with the FDA have helped us understand the current regulatory status, and he has a practice, which recently has passed their scrutiny. At the Andrews Research and Education Institute, we look forward to collaborating with him and to applying his technology in a compliant fashion. Working together we will produce evidence about the value of stem cell therapy for the treatment of joint injuries and degeneration, which will help us treat our patients better."
According to Dr. Josh Hackel, "We have recognized IntelliCell BioSciences as a forward thinking company and we are excited to continue FDA compliant research in this area as it relates to sports medicine and the treatment of our patients. It will be research like this at the Andrews Research and Education Institute in collaboration with IntelliCell BioSciences that will further our understanding and improve our management of sports medicine injuries."
http://ih.advfn.com/p.php?pid=nmona&article=61476597
As per Dr. Zain Khalpey, cardiac surgeon and member of SVFC's advisory board, "I would rather not put you on the list for transplant, I would rather take your fat-derived stem cells, inject them into you and try to use the device as a bridge to regenerate your heart, rather than using transplanted tissue, where you have to be on immunosuppression for the rest of your life. I believe that with the use of cavitation technology to harvest the stromal vascular fraction from a lipoaspirate without chemicals and enzymes, we would be able to capture the appropriate stem cells with their micromatrix and microenvironment for use in patients with failing hearts and lungs."
http://www.marketwatch.com/story/intellicell-biosciences-announces-that-dr-zain-khalpey-has-joined-its-advisor
http://surgery.arizona.edu/faculty-profile/zain-khalpey-md-phd-mrcs
GO SVFC $$$$$
all credit for this post belongs to Cazual
before you buy one single share of SVFC let me tell you!!! You better be prepared to be very rich, very soon!! SVFC will be the world leader in regenerative medicine with a U.S. patent already granted and an international patent in the final stages of being granted! SVFC is working with and is partnered with the worlds best Doctors and clinics and revenues are just beginning to come in! Please do some DD and you will see that SVFC is a life changing opportunity that you will not want to miss out on.
Here is a great link to some great DD from poster Cazual to get you started
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=101669938
SVFC is going up!!!
One thing for sure. SVFC is a once in a lifetime opportunity to turn $10,000 into well over $1,000,000 in very short order! And I believe the time is near, or should I say here?
Next week will be very very interesting
Go SVFC
Then there's only one way for the pps to go......
UP
SVFC
SVFC Watch for the bounce!
Let's just wait and see what happens next week, shall we? Nobody throws $40k at a sub-penny stock unless they know something. Oh wait, I got over $40k in this!!!
Hmmm
30 million shares bought @ .0014 in the last 30 minuets! Something is up...
And Monday it will be SVFC's pps
SVFC is going to rock!!!
Spread the word
I agree!!! Next week we ride the bollies
Just got me another 600k @ .0014 Whoo Hoo!
SVFC
Yes!!! SVFC is oversold!!!
Watch for the bounce
it's called manipulation. Use it to you're advantage and buy now. Because soon they will change it back and start to push it up.
All the nay sayers are using fear to get as many shares as possible. Don't be fooled!
there are some very strong forces at work manipulating this stock and if you play you're cards right you can become very rich!!!
DON'T BE FOOLED
SVFC
SVFC oversold
bounce time
Picked up 600k more@.0014 today :)
I now have over 23 million avg of.0018
I will keep adding at these levels until the manipulation is over. Then SVFC will fly into penny land!!!
It doesn't matter why I feel that SVFC is going to be a rockstar of a stock. Do you're homework and make you're own decision. Like I said buy or sell makes no difference to me.
Intellicell biosciences the company is moving forward with their corporate plan and is strengthening their balance sheet and expanding revenue generating options. The company is getting stronger and the stock will follow. Buy, sell, pump or bash this stock all you want. The day will come when SVFC will take on a life of its own and make massive moves up for many weeks, months and years! SVFC is going to be a one in a million stocks where a $10,000 investment will support you and your kids for the rest of your and their lives!
I'm buying more and not selling until dollar land!!
Go SVFC